AmplifyBio

AmplifyBio is a biopharmaceutical company that spun out from Battelle in 2021. As a premier Contract Research Organisation (CRO) and Contract Manufacturing Organisation (CMO/CDMO), AmplifyBio leverages decades of experience in designing and delivering in vivo safety, efficacy, and toxicology studies. The company assists in the preparation of Investigational New Drug (IND) packages and has steadily expanded its service offerings to support the discovery, characterization, optimization, and manufacturing of a diverse range of drug modalities. AmplifyBio has established itself as the industry’s preferred partner for advanced therapy development and commercialization, helping to reduce timelines and mitigate risks through the integration of expertise, assay technologies, and data solutions.

Services include:
- Biologics
- Cell and Gene Therapy
- Finished Dosage Formulation
- Excipients
- Oligonucleotide Supplier
- Plasmid Supplier
- Viral Vector Supplier
- Cold Storage

AmplifyBio continues to be at the forefront of the biopharmaceutical industry, providing critical services to enhance drug development processes. For more information, visit amplify-bio.com.